Efficacy of Liposomal Bupivacaine and Bupivacaine Hydrochloride vs Bupivacaine Hydrochloride Alone as a Periarticular Anesthetic for Patients Undergoing Knee Replacement: A Randomized Clinical Trial

医学 布比卡因 麻醉 可视模拟标度 不利影响 随机对照试验 局部麻醉剂 骨关节炎 外科 患者满意度 内科学 病理 替代医学
作者
Thomas William Hamilton,Ruth Knight,Jamie R. Stokes,Ines Rombach,Cushla Cooper,Loretta J Davies,Susan Dutton,Karen Louise Barker,Jonathan Alistair Cook,Sarah E Lamb,David W. Murray,Lisa Poulton,Ariel Wang,Louise H H Strickland,Bernard Hendrik van Duren,José Leal,David John Beard,Hemant G. Pandit,Study of Peri-Articular Anaesthetic for Replacement of the Knee (SPAARK) Study Group,Kirti Mohalkar
出处
期刊:JAMA Surgery [American Medical Association]
卷期号:157 (6): 481-481 被引量:94
标识
DOI:10.1001/jamasurg.2022.0713
摘要

Importance: More than half of patients who undergo knee replacement surgery report substantial acute postoperative pain. Objective: To evaluate the efficacy and cost-effectiveness of periarticular liposomal bupivacaine for recovery and pain management after knee replacement. Design, Setting, and Participants: This multicenter, patient-blinded, pragmatic, randomized clinical superiority trial involved 533 participants at 11 institutions within the National Health Service in England. Adults undergoing primary unilateral knee replacement for symptomatic end-stage osteoarthritis were enrolled between March 29, 2018, and February 29, 2020, and followed up for 1 year after surgery. Follow-up was completed March 1, 2021. A per-protocol analysis for each coprimary outcome was performed in addition to the main intention-to-treat analysis. Interventions: Two hundred sixty-six milligrams of liposomal bupivacaine admixed with 100 mg of bupivacaine hydrochloride compared with 100 mg of bupivacaine hydrochloride alone (control) administered by periarticular injection at the time of surgery. Main Outcome and Measures: The coprimary outcomes were Quality of Recovery 40 (QoR-40) score at 72 hours and pain visual analog scale (VAS) score area under the curve (AUC) from 6 to 72 hours. Secondary outcomes included QoR-40 and mean pain VAS at days 0 (evening of surgery), 1, 2, and 3; cumulative opioid consumption for 72 hours; functional outcomes and quality of life at 6 weeks, 6 months, and 1 year; and cost-effectiveness for 1 year. Adverse events and serious adverse events up to 12 months after randomization were also assessed. Results: Among the 533 participants included in the analysis, the mean (SD) age was 69.0 (9.7) years; 287 patients were women (53.8%) and 246 were men (46.2%). Baseline characteristics were balanced between study groups. There was no difference between the liposomal bupivacaine and control groups in QoR-40 score at 72 hours (adjusted mean difference, 0.54 [97.5% CI, -2.05 to 3.13]; P = .64) or the pain VAS score AUC at 6 to 72 hours (-21.5 [97.5% CI, -46.8 to 3.8]; P = .06). Analyses of pain VAS and QoR-40 scores demonstrated only 1 statistically significant difference, with the liposomal bupivacaine arm having lower pain scores the evening of surgery (adjusted difference -0.54 [97.5% CI, -1.07 to -0.02]; P = .02). No difference in cumulative opioid consumption and functional outcomes was detected. Liposomal bupivacaine was not cost-effective compared with the control treatment. No difference in adverse or serious adverse events was found between the liposomal bupivacaine and control groups. Conclusions and Relevance: This study found no difference in postoperative recovery or pain associated with the use of periarticular liposomal bupivacaine compared with bupivacaine hydrochloride alone in patients who underwent knee replacement surgery. Trial Registration: isrctn.com Identifier: ISRCTN54191675.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
科目三的应助被LDY采纳,获得10
1秒前
1秒前
1秒前
慢施发布了新的文献求助10
2秒前
Zbmd完成签到,获得积分0
2秒前
天天快乐的应助被Flong采纳,获得10
3秒前
bocchi完成签到,获得积分10
3秒前
水水完成签到 ,获得积分10
3秒前
3秒前
JOYCE发布了新的文献求助10
4秒前
4秒前
玩家666发布了新的文献求助10
4秒前
Hello的应助被朴实孤容采纳,获得40
4秒前
黑米粥发布了新的文献求助200
4秒前
bkagyin的应助被Su采纳,获得150
5秒前
yaoyinlin发布了新的文献求助10
5秒前
workingqi完成签到,获得积分20
5秒前
JamesPei的应助被piccolovegeta采纳,获得10
5秒前
6秒前
6秒前
单薄枕头发布了新的文献求助10
6秒前
7秒前
8秒前
优美绿草发布了新的文献求助10
9秒前
小二郎的应助被CHEN采纳,获得10
9秒前
10秒前
parny完成签到 ,获得积分10
10秒前
10秒前
WhyD发布了新的文献求助10
11秒前
Lucia发布了新的文献求助10
11秒前
anna完成签到,获得积分10
11秒前
wxm的应助被刘晏采纳,获得10
11秒前
嘟嘟完成签到 ,获得积分10
11秒前
专注的半雪的应助被shidewu采纳,获得10
11秒前
在水一方的应助被俭朴的毛巾采纳,获得10
12秒前
12秒前
12秒前
香蕉觅云的应助被yian007采纳,获得80
12秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178449
求助须知:如何正确求助?哪些是违规求助? 9569267
关于积分的说明 21803160
捐赠科研通 7773332
什么是DOI,文献DOI怎么找? 3432799
关于科研通互助平台的介绍 2556833
邀请新用户注册赠送积分活动 2478436